SS‑31 (Elamipretide) Peptide Explained: Mitochondria, Energy, and Safety for Everyday Readers

What Is SS-31 in Plain Language?

SS-31 (also known as elamipretide, Bendavia, and MTP-131) is a small synthetic peptidedesigned to go straight into the “power plants” inside our cells, called mitochondria. Mitochondria make ATP, the basic energy currency of the cell. When they are damaged, cells can’t work well, especially in energy-hungry tissues like heart, muscles, brain, and kidneys.

SS-31 is built from just four amino acids (D-Arg-2′6′-dimethylTyr-Lys-Phe-NH₂) arranged in a way that lets it cross cell membranes and accumulate specifically in mitochondria. Inside mitochondria, it binds to a special fat called cardiolipin, which is crucial for keeping the inner mitochondrial membrane and energy-making machinery stable.

In simple terms, SS-31 is being studied as a “mitochondrial protector” that may help stressed or damaged cells make energy more efficiently and handle oxidative stress better.

Why Are People Interested in SS-31?

Because mitochondrial problems show up in many conditions—heart failure, kidney disease, rare genetic mitochondrial disorders, and possibly aspects of aging—there is a lot of interest in a drug that directly targets mitochondrial health.

Key reasons SS-31 has attracted attention:

• It has shown protective effects in animal models of heart attack, kidney injury, and other energy-related problems.
• Human trials suggest possible benefits in rare mitochondrial diseases like Barth syndrome and primary mitochondrial myopathy, with some functional improvements over time.
• In 2025, elamipretide became the first FDA-approved therapy for a mitochondrial disease (Barth syndrome), based on clinical trial data showing improved mitochondrial function and patient outcomes.

At the same time, SS-31 has not worked in every trial (for example some heart failure and heart attack studies were neutral), reminding us that it is not a cure-all.

Main Uses and Potential Benefits

Areas with stronger human evidence

So far, the clearest human data for SS-31/elamipretide are in:

• Barth syndrome (a rare inherited mitochondrial disorder)
• Trials showed that ongoing subcutaneous elamipretide improved measures such as 6-minute walk distance, muscle strength, cardiac parameters, and patient-reported symptoms over many weeks.
• This led to FDA approval as a targeted therapy for Barth syndrome.
• Primary mitochondrial myopathy and related mitochondrial diseases
• Phase 2/3 studies have reported improvements in exercise capacity, walk distance, and quality-of-life scores in some cohorts, although results have been mixed and not every endpoint was met.

These are still relatively small, specialized populations, but they suggest SS-31 can meaningfully support mitochondrial function in certain rare disorders.

Areas with early or limited evidence

Other research areas include:

• Heart failure and ischemic heart disease
• A phase 2 heart failure trial found that daily subcutaneous SS-31 for 28 days was generally well tolerated but did not significantly change some primary cardiac function measures, although there were hints of benefit in certain subgroups.
• In acute heart attack (myocardial infarction) settings, SS-31 did not significantly reduce infarct size overall, but there were suggestions of reduced early heart failure events in some analyses.
• Chronic kidney disease and kidney ischemia-reperfusion injury
• Animal and early clinical studies show that SS-31 can protect kidney mitochondria, reduce oxidative stress, and improve structural and functional kidney markers after ischemic injury.

These areas remain promising but not definitive; more and larger trials are ongoing.

Speculative or experimental ideas

SS-31 is sometimes discussed in the context of:

• General “anti-aging” or longevity
• Performance enhancement or “energy boosting” in healthy people

At this stage, these ideas are speculative. Most data come from disease models or seriously ill patients, not healthy adults, and no large trials support SS-31 as a generic anti-aging or performance supplement.

What Research Studies Show

Animal and preclinical studies

Across many animal models, SS-31 has been reported to:

• Bind to cardiolipin in the inner mitochondrial membrane, stabilizing mitochondrial structure and function.
• Reduce mitochondrial reactive oxygen species (ROS) and lipid peroxidation—essentially lowering “oxidative stress.”
• Improve ATP production and electron transport chain efficiency.
• Protect mitochondria from swelling, cristae damage, and permeability-transition pore opening after ischemia (low blood flow) and reperfusion (blood flow restoration).
• Lessen tissue damage and improve functional recovery in models of heart attack, kidney ischemia, and certain muscle/nerve injuries.

For example, in rat heart-attack models, pretreatment with SS-31 reduced infarct size and markers of oxidative damage. In tafazzin-deficient mice (a model of Barth syndrome), SS-31 improved mitochondrial morphology and cardiac function.

Human clinical trials and case series

Key human findings include:

• Primary mitochondrial myopathy and Barth syndrome
• Multiple randomized, double-blind trials and open-label extensions showed that ongoing subcutaneous elamipretide could improve 6-minute walk distance, muscle strength, symptom scales, and some cardiac measures over months.
• Heart failure and cardiac conditions
• A heart failure trial found SS-31 was safe over 28 days, but primary outcomes (like changes in left ventricular volumes) were not significantly different from placebo, although some secondary measures and exploratory data looked favorable.
• A trial in patients undergoing heart attack interventions did not significantly reduce infarct size, though early heart failure events may have been modestly reduced.
• Kidney disease and other organ-specific studies
• Early work in kidney disease patients and high-risk procedures suggests mitochondrial protection and functional improvements, but study numbers are small and long-term data are limited.

Overall, human data show that SS-31 is biologically active and generally tolerable, with clear benefits in certain rare mitochondrial disorders and more mixed results in common conditions like heart failure. Sample sizes remain modest and follow-up time is limited.

How SS-31 Is Typically Taken

In clinical research and approved uses, SS-31/elamipretide is generally administered as:

• Subcutaneous injection (under the skin), often once daily
• In some early studies, intravenous (IV) infusions have also been used, especially in acute hospital settings

For subcutaneous injections, common sites include:

• Fatty tissue in the abdomen
• Outer thigh
• Sometimes the upper arm

Basic high-level principles are:

• Rotate injection sites to avoid repeatedly using the exact same spot.
• Avoid skin that is bruised, infected, or visibly irritated.
• Use sterile technique and single-use needles under medical guidance.

This article does not provide step-by-step instructions. All injectable use should be supervised by qualified healthcare professionals.

Dosing Patterns and Timing (Research Context)

Dosing varies by condition and trial, but common research patterns include:

• Daily subcutaneous injections over weeks to months, often at fixed doses (for example, 40 mg once daily in some mitochondrial disease trials).
• IV infusions over short periods in acute trials (such as around heart procedures).

Treatment duration:

• In rare mitochondrial diseases, ongoing daily dosing over many weeks to months has been used, with some open-label extensions extending to a year or more.
• In heart failure and acute heart attack trials, exposures were shorter (days to weeks).

Timing and daily routine:

• In studies, injections are typically given once a day, often at roughly the same time for consistency.
• There is no strict requirement to take SS-31 with or without food, but many patients choose a predictable morning or evening schedule, sometimes aligning with when they can best monitor how they feel.

For a structured research-dosing overview, see our separate dosing chart page for SS-31.

Side Effects and Safety Considerations

Common, usually mild-to-moderate effects

The most frequently reported side effects of subcutaneous elamipretide in trials have been injection-site reactions:

• Redness (erythema)
• Itching (pruritus)
• Pain or tenderness
• Swelling (induration)
• Small lumps or nodules
• Occasionally bruising or hives at the site

In multiple-dose trials, a majority of participants experienced some injection-site reaction. In one analysis, rates included roughly 47% with redness, 45% with itching, 22% with pain, 19% with induration, and smaller percentages with swelling, hives, bruising, or small masses.

These reactions are often described as mild to moderate and tend to improve over time or with site-rotation strategies.

Systemic side effects have generally been limited, with most studies reporting stable blood pressure, heart rate, and electrocardiogram readings. Fatigue, headache, or mild flu-like symptoms have been reported in some participants but are not universal.

“Signature” reactions

The most characteristic side effect profile for SS-31 is this cluster of injection-site issues—redness, itching, and mild swelling at the injection area. These typically appear shortly after injection and may last hours to a couple of days, often improving as the body adapts.

Rare but serious risks

Serious adverse events have been uncommon but can include:

• Severe allergic reactions (anaphylaxis): sudden hives, swelling of the face or throat, difficulty breathing, chest tightness.
• Worsening of pre-existing conditions (for example, a case of worsened kidney function in a participant who already had chronic kidney disease).

Any severe or rapidly worsening symptoms—trouble breathing, chest pain, widespread rash or swelling, severe dizziness, or intense pain—require immediate medical attention.

People with complex medical histories (heart disease, kidney disease, autoimmune conditions, or multiple medications) should only consider SS-31 under close specialist supervision, ideally in the context of formal treatment or clinical trials.

Contraindications and Who Should Be Cautious

Because SS-31/elamipretide is a prescription, targeted therapy (and in many settings still investigational), formal inclusion and exclusion criteria are defined in trial protocols rather than broad over-the-counter rules. Generally:

• Avoid or use extreme caution in:
• People with a history of severe allergic reactions to SS-31 or any of its components.
• Individuals with very fragile kidney or liver function, unless closely monitored in a specialist setting.
• Situations outside properly supervised medical care—this is not a DIY research compound for home use.
• Special populations
• Pregnant or breastfeeding individuals are usually excluded from trials; safety has not been established in these groups.
• Children and adolescents, except in specific pediatric mitochondrial disease studies, require specialist oversight.

Drug interactions are still being studied, but because SS-31 acts mainly inside mitochondria, classic drug-drug interactions are less well characterized than for many other medications. Even so, combining it with other experimental therapies or medications that stress the kidneys, heart, or liver should only be done under expert guidance.

Given the evolving evidence base and the seriousness of conditions being studied, a cautious, conservative approach with full medical oversight is essential.

Injection-Site Issues

As mentioned, injection-site reactions are very common with subcutaneous SS-31. Typical local experiences:

• Small bump or lump where the injection was given
• Redness, itching, or a warm feeling at the site
• Mild soreness or tenderness

General safety tips used in trials include:

• Rotating injection sites (for example, alternating areas of the abdomen or thighs) to reduce local irritation.
• Avoiding injection into areas that are already bruised, scarred, infected, or inflamed.
• Monitoring for signs of infection: increasing redness, warmth, pain, pus, or fever.

Any persistent, spreading, or unusually painful reaction—especially if accompanied by fever, chills, or feeling unwell—should be checked by a healthcare professional.

Cycling and Breaks

In contrast to some “biohacking” peptides used in informal cycles, SS-31 has mainly been studied as:

• Continuous daily therapy over weeks to months for mitochondrial diseases and chronic conditions.
• Shorter courses in acute settings (like heart procedures or kidney injury models).

Reasons to pause or stop therapy in research include:

• Significant side effects or injection-site reactions that become intolerable.
• Changes in kidney, liver, or heart function that raise safety concerns.
• Lack of benefit after a defined trial period, as judged by the treating team.

There is no universally accepted “on/off” cycle protocol for SS-31. In real-world care, decisions about continuing, adjusting, or pausing treatment are individualized and always made with a specialist team.

Practical “Real-World” Tips (Educational Only)

From an educational perspective—and not as medical advice—several themes emerge from clinical reports and patient experiences:

• Expect injection-site reactions: Many participants notice redness, itching, or mild swelling at the injection site, especially early on.
• Site rotation helps: Moving injections around different areas of the abdomen or thighs tends to reduce repeated irritation.
• Report new symptoms early: Any new or worsening fatigue, swelling, breathing changes, or unusual pain should be discussed quickly with the care team.
• Regular monitoring matters: Lab tests (kidney function, liver function, blood counts) and clinical exams are used in trials to catch issues early and adjust dosing.

Because SS-31 is designed for serious mitochondrial conditions, it should be thought of as a specialized medication requiring close oversight—not as a general wellness peptide.